全文获取类型
收费全文 | 4997篇 |
免费 | 481篇 |
专业分类
水产渔业 | 1篇 |
畜牧兽医 | 5477篇 |
出版年
2024年 | 7篇 |
2023年 | 90篇 |
2020年 | 167篇 |
2019年 | 2篇 |
2018年 | 122篇 |
2017年 | 134篇 |
2016年 | 86篇 |
2015年 | 140篇 |
2014年 | 225篇 |
2013年 | 242篇 |
2012年 | 181篇 |
2011年 | 209篇 |
2010年 | 164篇 |
2009年 | 244篇 |
2008年 | 151篇 |
2007年 | 95篇 |
2006年 | 81篇 |
2005年 | 81篇 |
2004年 | 143篇 |
2003年 | 147篇 |
2002年 | 166篇 |
2001年 | 159篇 |
2000年 | 122篇 |
1999年 | 118篇 |
1998年 | 171篇 |
1997年 | 179篇 |
1996年 | 159篇 |
1995年 | 159篇 |
1994年 | 138篇 |
1993年 | 151篇 |
1992年 | 174篇 |
1991年 | 147篇 |
1990年 | 186篇 |
1989年 | 131篇 |
1988年 | 113篇 |
1987年 | 145篇 |
1986年 | 54篇 |
1985年 | 78篇 |
1984年 | 82篇 |
1983年 | 79篇 |
1982年 | 35篇 |
1981年 | 11篇 |
1980年 | 5篇 |
1977年 | 3篇 |
1962年 | 1篇 |
1961年 | 1篇 |
排序方式: 共有5478条查询结果,搜索用时 15 毫秒
71.
L.S. Faudskar DVM M. R. Raffe DVM MS D. A. Randall BS D. R. Bing BS RRT 《Journal of Veterinary Emergency and Critical Care》1997,7(1):49-58
A laboratory evaluation was performed to evaluate the performance characteristics of a new veterinary ventilator. The ventilator studied was configured according to manufacturer's directions and attached to a test lung via a pneumotachograph and differential pressure transducer interfaced to a pulmonary mechanics analyzer system. Constant resistance (R=10 cm H2 O/L/sec) and compliance (C=3 ml/cm H2 O) factors were maintained for all trials. The ventilator operated at the manufacturer's preprogrammed parameters. In the first trial, body weight was the only variable. In the second trial, an endotracheal tube was placed in series between the ventilator's breathing circuit and the pneumotachograph. Body weights from 1–20 kgs were evaluated. Mean values for respiratory rate (RR), minute ventilation (VE), inspiratory time (Ti), peak inspiratory pressure (PIP), and peak inspiratory flow (Fpki) displayed on the ventilator control panel; tidal volume (VT), calculated from the displayed minute volume, and identical parameters measured by the pulmonary mechanics system at each body weight, were compared using a two factor analysis of variance. Significant differences (P< 0.05) were found between mean displayed and measured values for RR, PIP, and Fpki. 相似文献
72.
Pharmacokinetic and Phase I Evaluation of Carboplatin in Dogs 总被引:1,自引:1,他引:0
Rodney L. Page DVM MS Margaret C. McEntee DVM Steven L. George PhD Patrick L. Williams PhD Greta L. Heidner DVM Carol A. Novotney DVM Jim E. Riviere DVM PhD Mark W. Dewhirst DVM PhD Donald E. Thrall DVM PhD 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》1993,7(4):235-240
Thirty dogs with spontaneously occurring malignant neoplasms were treated monthly with carboplatin (CBDCA) given as a 30-minute intravenous infusion in a dose escalation study. Twenty-eight dogs were considered evaluable for toxicity. The maximally tolerated dose of CBDCA was conceptually defined as that dose, determined by logistic regression analyses of toxicity data, resulting in a 50% incidence of moderate toxicity (MOD50) or a 5% incidence of severe toxicity (SEV5). Each designated maximally tolerated dose was calculated for the first course of treatment only and for the first and second courses of treatment combined to estimate cumulative drug toxicity. The MOD50 and SEV5 for the first treatment course were 340 and 278 mg/M2, respectively. MOD50 and SEV5 values for the first plus second treatment courses were 327 and 231 mg/M2, respectively. The nadir of neutrophil and platelet counts occurred approximately 14 days after treatment. The mean neutrophil and platelet values for all dogs experiencing myelosuppression during the first two treatment courses were 1541/μL and 62,600/μL, respectively. Nonparametric pharmacokinetic analysis of plasma CBDCA values suggested that half-life (T1/2), area-under-the-curve and total body clearance (CLb) were not dose dependent. Volume of distribution (VDss) significantly increased with dose only between 100 and 150 mg/M2, not between 150 and 300 mg/M2. Dose-independent serum CBDCA pharmacokinetic disposition indicates that detailed investigation of tissue CBDCA distribution would be warranted and may identify novel dosing strategies that could improve the therapeutic index of CBDCA by minimizing toxicity. (Journal of Veterinary Internal Medicine 1993; 7:235–240. Copyright © 1993 by the American College of Veterinary Internal Medicine.) 相似文献
73.
Daniel J. Burba DVM Michael A. Collier DVM Lawrence E. Default PhD Olivia Hanson-Painton PhD Harold C. Thompson Jr. Claude L. Holder 《Journal of Equine Veterinary Science》1993,13(12):696-703
The uptake and distribution of intramuscularly (IM) administered tritium-labeled polysulfated glycosaminoglycan (3H-PSGAG) in serum, synovial fluid, and articular cartilage of eight horses was quantitated, and hyaluronic acid (HA) concentration of the middle carpal joint was evaluated in a pharmacokinetic study. A full-thickness articular cartilage defect, created on the distal articular surface of the left radial carpal bone of each horse served as an osteochondral defect model. 3H-PSGAG (500 mg) was injected IM, between 14 and 35 days after creation of the defects. Scintillation analysis of serum and synovial fluid, collected from both middle carpal joints at specific predetermined times up to 96 hours post-injection, revealed mean 3H-PSGAG concentrations peaked at 2 hours post-injection. 3H-PSGAG was detected in cartilage and subchondral bone 96 hours post-injection in samples from all eight horses. There were no statistically significant differences in 3H-PSGAG concentration of synovial fluid or cartilage between cartilage defect and control (right middle carpal) joints.
HA assay of synovial fluid revealed concentrations significantly increased at 24, 48, and 96 hours post-injection in both joints. The concentration nearly doubled 48 hours post-injection. However, no statistically significant differences were found between synovial concentrations of HA in cartilage defect and control joints.
3H-PSGAG administered IM to horses, was distributed in the blood, synovial fluid, and articular cartilage. HA concentrations in synovial fluid increased after IM administration of polysulfated glycosaminoglycan. 相似文献
74.
KAREN J. FRISCHMEYER dvm PAUL E. MILLER dvm diplomate acvo YVONNE BELLAY dvm MS STEPHANIE L. SMEDES DVM Diplomate ACVO DAVID B. BRUNSON dvm MS Diplomate ACVA 《Veterinary surgery : VS》1993,22(3):230-234
Dogs given parenteral anticholinergic drugs have been thought to be at risk for development or exacerbation of elevated intraocular pressure (IOP). In a randomized, blinded, placebo-controlled study, we evaluated the effect of intramuscular glycopyrrolate (0.01 mg/kg) on pupil diameter and IOP in unanesthetized normal dogs. Treatment with glycopyrrolate did not change pupil diameter or IOP from baseline, nor were there differences between glycopyrrolate and saline-treated (control) dogs. In addition, the authors retrospectively reviewed the medical records of 2,828 dogs undergoing general anesthesia between April 1987 and September 1990 to determine if there was an association between parenteral anticholinergic medication and postanesthetic elevation in IOP. The authors also determined the frequency of bradycardia requiring anticholinergic therapy during anesthesia in dogs with glaucoma. Of the 2,828 cases reviewed, the records of 46 dogs coded for glaucoma were examined in detail. The 46 dogs underwent 62 episodes of anesthesia, with 23 episodes including exposure to an anticholinergic drug. An increase in IOP from preanesthetic to postanesthetic measurement occurred in three dogs. One of these dogs received anticholinergic medication for bradycardia during anesthesia. The postanesthetic elevation in IOP in this dog was probably not drug related. Preanesthetic anticholinergic administration did not affect the incidence of anticholinergic administration for bradycardia during the anesthetic episode. Anticholinergic therapy during anesthesia was more frequent when the preanesthetic medication included an opiate drug. These studies do not indicate an association between parenteral anticholinergic administration and elevations in IOP. 相似文献
75.
Mitchell A. Crystal DVM Dominique G. Penninck DVM Michael E. Matz DVM Susan H. Pearson BA Greg O. Freden DVM Richard M. Jakowski DVM 《Veterinary radiology & ultrasound》1993,34(6):438-444
The purpose of this study was to evaluate the usefulness of ultrasound-guided fine-needle aspiration biopsy and core biopsy in the diagnosis of infiltrative gastrointestinal diseases. Six dogs and seven cats with clinical signs of gastrointestinal disease underwent ultrasonography and intestinal lesions were identified. One or more ultrasound-guided fine-needle aspiration biopsy and/or core biopsy procedures were performed in each patient. Each patient also underwent one of the following additional procedures for comparison of results: 1) surgery (n=4), 2) endoscopy (n=2), 3) post mortem exam (n=3), and, 4) for lymphoma diagnosed with ultrasound-guided procedures, response to chemotherapy (n=4). Correct diagnoses were obtained in nine of the 13 patients, incorrect diagnoses in two of the 13 patients, and inconclusive diagnoses in two of the thirteen patients. Of the 16 total ultrasound-guided procedures performed, ten were confirmed as correct, three as incorrect, and three were non-diagnostic. Intestinal lesions with bowel wall thickness greater than 2.0 cm had a higher percentage of correct diagnoses than lesions of lesser wall thickness. Gastric lesions had a higher percentage of correct diagnoses than small and large intestinal lesions. Malignant lesions had a higher percentage of correct diagnoses than benign lesions. There were no complications. Ultrasound-guided gastrointestinal fine-needle aspiration biopsy and core biopsy appears to be a safe, accurate, and rapid procedure for use in the diagnosis of infiltrative gastrointestinal disease. 相似文献
76.
77.
Benny J. Woody DVM MS Michael J. Murphy DVM PhD AIlen C. Ray PhD Robert A. Green DVM PhD 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》1992,6(1):23-28
The clinical signs and laboratory changes of brodifacoum (BDF) intoxicated dogs and their response to vitamin K1 treatment were examined. Brodifacoum, a second-generation anticoagulant rodenticide, was fed to four dogs for 3 consecutive days producing a cumulative dose of 1.1 mg BDF/kg body weight. Clinical observations of the animals were made daily throughout the study. Monitored laboratory parameters included: one-stage prothrombin time (OSPT), activated partial thromboplastin time (APTT), activated coagulation time (ACT), complete blood counts, thrombocyte counts, and serum chemistry values. Response to vitamin K1 therapy was evaluated clinically and by laboratory tests. Serum BDF concentrations were monitored. Inappetence and hemorrhagic tendencies were exhibited by day 5 postrodenticide exposure. One-stage prothrombin time, APTT, and ACT were 25% greater than time zero values at 24, 24, and 72 hours postdosing, respectively. All laboratory parameters returned to normal within 48 hours of initiating vitamin K1 therapy (0.83 mg/kg orally, TID for 5 days). Serum brodifacoum concentrations were highest (1065-1215 ng/mL) during the 3 days after BDF dosing and were detectable (3.0-7.5 ng/mL) until day 24 postexposure. A mean BDF elimination half-life of 6 +/- 4 days was observed. 相似文献
78.
79.
80.